Sveikata iš gamtos, MB - financials and debts

Company age: 4 y. 1 mo.

Update

Sveikata iš gamtos - Company finances

EUR
2022
From: 2022-08-05
To: 2022-12-31
2023
From: 2023-01-01
To: 2023-12-31
2024
From: 2024-01-01
To: 2024-12-31
2025
From: 2025-01-01
To: 2025-12-31
Financial data
Sales revenue 15,909 66,207 72,643 87,175
Profit before tax 351 2,605 3,638 6,381
Net profit 351 2,466 3,447 5,998
Equity 451 2,917 6,364 12,362
Liabilities 6,290 7,367 6,698 10,300
Non-current assets 0 0 0 0
Current assets 6,741 10,284 13,062 22,662
Total assets 6,741 10,284 13,062 22,662
Taxes paid
STI taxes - 3,515 3,650 6,066
Financial indicators
Revenue change y/y - +316.2% +9.7% +20.0%
ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. 5.2% 24.0% 26.4% 26.5%
ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. 77.8% 84.5% 54.2% 48.5%
Profit margin Net profit margin. Shows the overall profitability of the company. 2.2% 3.7% 4.7% 6.9%
EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. 2.2% 3.9% 5.0% 7.3%
Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. 13.9 2.5 1.1 0.8
Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. - - - -

Purchase full financial statements

Profit/Loss, Balance Sheet, Cash Flow, Equity

9.99 € + PVM Buy

See Scoris data in Google Search

Mark Scoris as a favorite source. One click, no registration.

Sveikata iš gamtos - Social security debts

The company had no debts to Sodra

Sveikata iš gamtos - VMI tax arrears

From To Overdue, €
2025-06-28 2025-07-25 0.23
2025-06-19 2025-06-19 0.04

VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.

Analysis of the company's financial position

This description was generated by artificial intelligence. Report if inaccurate.
Sveikata iš gamtos, MB (code 306127616) is a Lithuanian small partnership engaged in retail sale of pharmaceutical products. In the latest year, 2025, revenue reached €87.2K, increasing by 20.0% year on year and by 31.7% compared with 2023. Net profit rose to €6.0K in 2025 from €3.4K in 2024 and €2.5K in 2023, showing a steady upward trajectory over the three-year period. Profitability also improved, with the net profit margin increasing from 3.7% in 2023 to 4.7% in 2024 and 6.9% in 2025. The balance sheet strengthened as total assets grew to €22.7K in 2025, equity increased to €12.4K, and liabilities reached €10.3K. The equity ratio stood at 54.5%, debt-to-equity at 0.83, and asset turnover at 3.85x. ROE was 48.5% and ROA 26.5% in 2025, consistent with improved earnings generation relative to the company’s asset base.